New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Volume 1, # 2/3 - June/July, 1995

Table of Contents

STATE-OF-THE-ART MANAGEMENT OF CANCER
CANCERS OF THE DIGESTIVE SYSTEM - PART II
Screening, Diagnosis and Monitoring 34
  Esophageal Cancer 34
  Stomach Cancer 34
  Live Cancer 35
  Pancreatic Cancer 36
  Colorectal Cancer 37
    Occult blood 37
    Flexible sigmoidoscopy 37
    Tumor markers 38
    Genetic testing 38
    Screening of high risk groups 38
    Radioimmunoscintigraphy 39
  Gallbladder Cancer 39
  Cancer of the Small Intestine 39
  Anal Cancer 40
Current Therapy 40
  Esophageal Cancer 40
  Stomach Cancer 41
  Primary Hepatocellular Carcinoma (HCC) 41
  Metastatic Neoplasms of the Liver 42
    Regional therapy 43
    Chemoembolization 44
    Radiotherapy 44
    Liver transplants 45
    Other therapies 45
  Neoplasms of the Extrahepatic Bile Ducts 45
  Pancreatic Cancer 46
  Colorectal Cancer 47
  Gallbladder Cancer 49
  Cancer of the Small Intestine 49
  Anal Cancer 50
New Drugs and Allied Therapies in Development 50
  Gene Therapy/Vaccines/Immunomodulating Agents/Monoclonal Antibodies 51
    Aphton 51
    Biomira 51
    Bristol-Myers Squibb 51
    Canji 51
    Centocor 52
    Corixa 52
    Cytel 52
    Genetics Institute 52
    ImClone 52
    Immune Response 53
    Immunomedics 53
    ImmunoTherapeutics 53
    Jenner Technologies 53
    NeoRx 53
    Seragen 53
    Somatix Therapy 53
    StressGen Biotechnologies 53
    Therion Biologics 54
    University of Alabama 54
    Vical 54
    The Wistar Institute 54
  Thymidylate Synthase Inhibitors 54
    ZD1694 55
    AG337 and AG331 55
    UFT 55
  Topoisomerase I Inhibitors 56
    CPT-11 56
  Drug Delivery 56
    Liposomes 56
    Matrix Pharmaceutical 56
    Sparta Pharmaceuticals 56
  Photodynamic Therapy (PDT) 56
MEETING COVERAGE
RADIOIMMUNOSCINTIGRAPHY IN CANCER DIAGNOSIS
A Report From the Tenth International Conference on Monoclonal Antibody Immunoconjugates for Cancer
March 9-11, 1995 - San Diego, CA
Challenges Facing MAb-Based Radioscintigraphy 65
  Radioisotope Choice 65
  Development of MAbs for in vivo Imaging Applications 65
    Targeting growth factors or oncogenes 65
    MAb fragments 65
    MAb dosing requirements 67
    SPECT imaging 67
Selected Diagnostic Applications 67
  Colorectal Cancer 67
  Pancreatic Cancer 68
  Hodgkin's Lymphoma 68
Clinical Challenges to Radioimmunoscintigraphy 69
  Increasing Scintigraphic Contrast 70
    Pretargeting 69
    Enhancing Tumor Access 70
  Reducing Antibody Immunogenicity 71
    Human MAbs 71
  Assessing True Benefit of Radioimmunoscintigraphy 71
Intraoperative Use of Radioimmunoconjugates 72
  Radioimmunoguided Surgery (RIGS) 72
  Beta-ray Systems 72
HIGHLIGHTS OF DIGESTIVE DISEASE WEEK
San Diego, CA - May 14-17, 1995
Gastric Malt Lymphoma and H.Pylori 73
Esophageal Cancer Treatments 73
  Multimodal Therapy 73
  Stents 73
Microwave Coagulation Therapy (MCT) in Liver Cancer 73
MECHANISMS IN MALIGNANCY
DRUG RESISTANCE IN CANCER - PART I
General Mechanisms of Drug Resistance 74
  Decreased Drug Accumulation 74
  Altered Drug Metabolism 74
  Increased Repair of Drug-Induced Damage 74
  Altered Gene Expression 74
In Vivo Drug Resistance Factors 75
Multidrug Resistance 75
  Classic (P-Glycoprotein-Dependent) MDR 75
  Other Gene Products in MDR 75
  MDR Associated With Topoisomerase Alterations 77
  Altered Expression of Drug-Metabolizing Enzymes and MDR 78
  Apoptosis in MDR 78
  Multiple Mechanisms in Drug-Resistant Tumors 78

HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887